1 / 69

Hormone Biosynthesis, Metabolism, and Mechanism of Action

Hormone Biosynthesis, Metabolism, and Mechanism of Action. Adrian Quesada Rojas, MD. Definitions. Hormone: Substance produced in tissue => bloodstream => responsive cells Provides means of communication chemical regulatory and signaling Bloodstream Paracrine: cell to cell (contiguos)

felice
Download Presentation

Hormone Biosynthesis, Metabolism, and Mechanism of Action

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Hormone Biosynthesis, Metabolism, and Mechanism of Action Adrian Quesada Rojas, MD

  2. Definitions Hormone: Substance produced in tissue => bloodstream => responsive cells Provides means of communication chemical regulatory and signaling Bloodstream Paracrine: cell to cell (contiguos) Autocrine: same cell Intracrine: same cell (unsecreted)

  3. Nomenclature Steroid hormones Sex steroids (Cholesterol derivatives) 3 groups (number of carbon atoms) 21 carbons: pregnane nucleus 19 carbons: androstane 18 carbons: estrane

  4. Nomenclature

  5. Lipoproteins and Cholesterol • All steroid prod organs can synth (acetate) LPP: transport of non polar fat in polar solvent • Chylomicrons: chlol 10, TG 90 formed in GI • VLDL: more dense • IDL: removal of some TG from VLDL interior • LDL: end prod VLDL catabolism (50% chol) • major carrier of chol in plasma • HDL: highest protein content

  6. Lipoproteins and Cholesterol

  7. Steroidogenesis • Reactions: Cleavage of side chain Conv hydroxyl <=> ketones (dehydrogenase) Addition of OH group (hydroxylation) Creation of double bonds (remov of H) Addition of hydrogen (saturation) Enz are dehydrogenases or C P450 oxidases

  8. Steroidogenesis • Rate limit step: transfer Chol from outer to inner mitochondrial membrane (SSC) • Once Pregnenolone: two ways in ovary D5pathway (3-b hydroxysteroids) => DHEA D4pathway (3-ketone) => 17a hydroxyP • Conversion of pregnenolone to P: 3b hydroxysteroid dehydrogenase D4-5isomerase reaction (3-OH group to ketone + transfer double bond 5-6 to 4-5)

  9. Steroidogenesis • P hydroxylated at 17 position 17a OH P (precursor of C19 androgens) By peroxide formation at C20, followed by epoxidation of C17, C20 carbons, side chain is split off forming Androstenedione • 17 ketone may be reduced to 17b OH to form testosterone (C 19) • C 19 steroids => aromatase => C18 phenolic steroid estrogen (E1 and E2)

  10. Steroidogenesis • Alternative Pregnenolone conv to D5 3b OH C19 steroid (DHA) by 17a OH lation followed by SCC With D4 3 ketone formation, DHA is converted into Androstenedione (C19 steroids) C 19 steroids undergo aromatization (hydroxylation of angular 19 methyl group, followed by oxydation and loss of 19 C as formaldehyde and dehydrogenation)

  11. Steroidogenesis

  12. Two Cell System • FSH receptors on granulosa • FSH receptors are induced by FSH • LH receptors on theca initially, as follicle grows FSH induces LH receptors on granulosa • FSH ind aromatase activity on granulosa • Actions regulated by autocrine and paracrine factors

  13. Two Cell System

  14. Blood Transport of Steroids • Most E and T bound to protein carrier (SHBG) • 30% is bound to albumin • 1% free Hyperthyroidism, pregnancy, E adm SHBG Corticoids, A, P, GH, Insulin SHBG SHBG inversely related to weight Hyperinsulinemia (low SHBG predictor of DM) Body fat distrib (central=> hyperinsulinemia)

  15. Blood Transport of Steroids

  16. Estrogen Metabolism • Ovary => Estradiol / estrone • Estriol => periph metab of estrone / E not a secretory prod of ovary conversion to less active form Androgens are precursors of estrogens Adrenal gland (source of A, Androstenedione)

  17. Estrogen Metabolism

  18. Estrogen Metabolism • E2 100-300 mg/day • Androstenedione 3 mg/day ( 1% conversion) => 20- 30 % of E1 (produced every day)

  19. Progesterone Metabolism • NO peripheral conversion • Secretion from adrenal and ovaries • Preov < 1 mg /day • Post ov 20-30 mg /day • 10-20% of P is excreted as Pregnanediol • Pre ov <1 mg/day, post ov 3-6 mg/d (home ovulation test)

  20. Androgen Metabolism • Ovary: DHA, Androstenedione, testosterone • Adrenal cortex: Gluco, mineralo, sex steroid • Sex steroids (less than ovary) • DHA (½ adrenal, ¼ ovary, ¼ periph) • Androstenedione (½ adrenal, ½ ovary) • Testost 0.2-0.3 mg/day • 50% periph conv of androstenedione and DHA • 25% adrenal • 25% ovary

  21. Androgen Metabolism • Androgens Test binding capacity • Androg effects depends on unbound fraction • Hirsutism • Test => 5a reductase => DHT (princ androg) • Androstenedione > Test (women) • DHT is derived from Androst and DHA • DHT largely metabolized intracell • Only 1/10 of levels of Test • Not all tissue requires DHT from Test (Wolffian)

  22. Cellular Mechanism of Action • Two major types of hormone action Tropic hormones (recep at cell memb) Steroids (recep inside the cell) • Multiple cell receptors: Intracellular: In the nucleus (transcription activity) G protein: Single polypeptide chain (cell memb)

  23. Cellular Mechanism of Action Ion gate channel: Cell surface, mult units (ACh) Intrinsic enz activ: Trans memb recep with intracell component with tyrosine or serine kinase activity

  24. Mechanism of actionSteroid hormones • Includes: • Hormone diffusion across cell memb • Steroid binding to receptor protein • Interaction of Horm-Recep complex with DNA • Synthesis of mRNA • Transport of mRNA to ribosomes • Protein synthesis in cytoplasm

  25. Mechanism of actionSteroid hormones

  26. Mechanism of actionSteroid hormones • Biological activity Mantained only while H-R complex attached to nuclear site Duration of exposure to hormone is as important as dose Major factor in potency differences among various estrogens is length of time E-R complex occupies nucleus

  27. Mechanism of actionSteroid hormones Cortisol and P must circulate in large concentrations 2 to receptor complexes short half-lives in nucleus H-R complex after gene activation (processing) Rapid degradation of R unbound to E Much slower degradation of bound R Continuous presence of E is important factor in continuing response

  28. Estrogen Receptors • ER-a (rapid turnover) • ER-b 96% homologous in DNA binding domain and 53% homologous in the hormone binding domain (when compared to ER-a) • Respond in comparable manner to same hormones

  29. Estrogen Receptors

  30. Estrogen Receptors • E receptors => nucleocytoplasmic shuttling • Recep can diffuse out of nucleus and be transported back in or undergo metabolism • If shuttling impaired Receptors are degraded rapidly • E antagonists prevent nuclear translocation and thus increase cytoplasmic degradation

  31. Estrogen Receptors • Prior to binding R is inactive complex that includes a variety of heat shock proteins • Activation => dissociation of HSP • When H binds R => conformational change • Conformational shape determines exact message transmitted to the gene • E2, raloxifene, tamoxifen induces a different conformational shape

  32. Estrogen Receptors • Once activated H receptor activates transcription in partnership with several groups of polypeptides • Transcription factors (polymerase enzyme and DNA) • Coactivators and corepressors (intracel prot called adaptor proteins and activate or suppress the TAF)

  33. Estrogen Receptors • Phosphorylation • Also stimulated by ligand binding • Occur in specific receptor sites • Increases potency of molecule to regulate transcription • cAMP and prot kinase pathways increase transcriptional activity of E-R

  34. Estrogen Receptors • Differences ER-a and ER-b ER-b prevalent in brain, CV system, granulosa cells Breast expresses ER-a and ER-b ER-b acts as natural suppressor of ER-a activity on breast tissue Colon contains only ER-b, reduction of colon CA in postmenopausal on HRT may reflect antiproliferative effect of beta receptor

  35. Progesterone Receptor • Induced by E, decreased by Progestins • Two major forms (A and B) • A and B are expressed differently in Breast and Endometrial tissues • In most cells B positive regulator of P-responsive genes, A inhibits B activity • A and B have different molecular functions, affecting different genes

  36. Progesterone Receptor • Mice lacking of P receptors (A,B) are unable to ovulate (failure to expel a mature oocyte in a fully developed follicle) • PR-A protects against uterine and mammary gland hyperplasia induced by PR-B

  37. Androgen Receptor • Androgens only in one of three ways: • T => DHT (Intracrine) • T itself (Endocrine) • Intracel conversion of T to E (Intracrine) • Wolffian duct derivatives (T) • Hair follicles, urogenital sinus derivatives (req T => DHT)

  38. Androgen Receptor • T and DHT binds to same high affinity A-receptor (DHT has greater affinity) • Anti-A also bind to same R (20% affinity of T) • A-R: two forms B (full length) and A (shorter) • Functional differences yet to be determined • A and P can cross react for their receptors (pharmacologic concentrations) • Progestin can act as an anti-E and anti-A

  39. Androgen Receptor • Androgen Insensitivity Syndrome Congenital abnormality in A intracel R A-R gene is on X chromosome (Xq11-12) X-linked disorder Deletion of amino acids from steroid binding domain 2 to nucleotide alterations in gene

  40. Androgen Receptor

  41. Agonists and Antagonists Agonist => stimulates response Antagonist => inhibits actions of an agonist blockage of receptor message • Examples: Tamoxifen Mifepristone Histamine receptor antag

  42. Agonists and Antagonists • Physiologic Antagonists P is not an E antagonist Modifies E action by depleting E receptors P can induce conversion of E2 to E1 Androgens block E actions (unclear mechan)

  43. Agonists and Antagonists • Two groups of anti-E: Pure anti-E Mixed agonists antagonists • Tamoxifen: Similar to clomiphene Competitively inhibits E binding to receptor E affinity for receptor is 100-1000x better than tamoxifen

  44. Agonists and Antagonists

  45. Agonists and Antagonists • Tamoxifen–E receptor binds to DNA • Agonistic – Antagonistic actions depends on coactivators present in specific cell types • Estrogenic actions: • Lowers FSH levels • Decreases Cholesterol, LDL • Stimulates P receptor synthesis • Maintenance of bone, vagina, endometrium

  46. Agonists and Antagonists • Causes endometrial hyperplasia, polyps and 4x increase in endometrial cancer • Mechanism of action: • TAF-1 and TAF-2 can both activate transcription • Tamoxifen agonistic ability is due to activation of TAF-1 • Antagonistic activity is due to competitive inhibition of E-dependent activation of TAF-2

  47. Estrogen Receptors

  48. Agonists and Antagonists • Response to E and anti-E depends on: • Nature of E receptor • E response elements and promoters • Cell content of protein coactivators • Properties of ligand • Modulation by growth factors and agents that affect phosphorylation and protein kinases

  49. Agonists and Antagonists • Tamoxifen reduces risk of recurrent disease in E-R positive and negative breast cancer • Besides binding to E-R (competitive inh), • Inhibits protein kinase C activity (phosphor) • Inhibits calmodulin-dependent cyclic AMP phosphodiesterase (binds to calmodulin) • Stim secretion of TGF-b (inh growth CA cell)

  50. Agonists and Antagonists • Tamoxifen: treatment should be for only 5 years • Emergence of tamoxifen-resistant tumors, how? Loss of E receptors • Loss of cellular control / loss of E-R expression • Variant and mutant E-R • Changes in coactivators • Differential metabolism • Resistance occur when E-R is NOT dominant in growth of CA cells

More Related